AU5441199A - Oral vaccine compositions - Google Patents

Oral vaccine compositions

Info

Publication number
AU5441199A
AU5441199A AU54411/99A AU5441199A AU5441199A AU 5441199 A AU5441199 A AU 5441199A AU 54411/99 A AU54411/99 A AU 54411/99A AU 5441199 A AU5441199 A AU 5441199A AU 5441199 A AU5441199 A AU 5441199A
Authority
AU
Australia
Prior art keywords
microparticles
oral vaccine
vaccine formulations
less
vaccine compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU54411/99A
Other languages
English (en)
Inventor
David James Brayden
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Perrigo Co PLC
Original Assignee
Elan Corp PLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elan Corp PLC filed Critical Elan Corp PLC
Publication of AU5441199A publication Critical patent/AU5441199A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/099—Bordetella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
AU54411/99A 1998-09-01 1999-08-31 Oral vaccine compositions Abandoned AU5441199A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9875998P 1998-09-01 1998-09-01
US60098759 1998-09-01
PCT/IE1999/000086 WO2000012124A1 (en) 1998-09-01 1999-08-31 Oral vaccine compositions

Publications (1)

Publication Number Publication Date
AU5441199A true AU5441199A (en) 2000-03-21

Family

ID=22270760

Family Applications (1)

Application Number Title Priority Date Filing Date
AU54411/99A Abandoned AU5441199A (en) 1998-09-01 1999-08-31 Oral vaccine compositions

Country Status (7)

Country Link
EP (2) EP2168593A1 (cg-RX-API-DMAC7.html)
JP (1) JP4601823B2 (cg-RX-API-DMAC7.html)
AT (1) ATE452651T1 (cg-RX-API-DMAC7.html)
AU (1) AU5441199A (cg-RX-API-DMAC7.html)
CA (1) CA2341352C (cg-RX-API-DMAC7.html)
DE (1) DE69941848D1 (cg-RX-API-DMAC7.html)
WO (1) WO2000012124A1 (cg-RX-API-DMAC7.html)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPR011700A0 (en) 2000-09-14 2000-10-05 Austin Research Institute, The Composition comprising immunogenic virus sized particles (VSP)
US7998507B2 (en) 2000-09-21 2011-08-16 Elan Pharma International Ltd. Nanoparticulate compositions of mitogen-activated protein (MAP) kinase inhibitors
US6977085B2 (en) 2000-12-22 2005-12-20 Baxter International Inc. Method for preparing submicron suspensions with polymorph control
US6607784B2 (en) 2000-12-22 2003-08-19 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
US6884436B2 (en) 2000-12-22 2005-04-26 Baxter International Inc. Method for preparing submicron particle suspensions
US9700866B2 (en) 2000-12-22 2017-07-11 Baxter International Inc. Surfactant systems for delivery of organic compounds
US7193084B2 (en) 2000-12-22 2007-03-20 Baxter International Inc. Polymorphic form of itraconazole
US8067032B2 (en) 2000-12-22 2011-11-29 Baxter International Inc. Method for preparing submicron particles of antineoplastic agents
US6951656B2 (en) 2000-12-22 2005-10-04 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
MXPA04002446A (es) 2001-09-26 2004-07-23 Baxter Int Preparacion de nanoparticulas de tamano de submicras mediante dispersion y remocion de la fase liquida o solvente.
US20060003012A9 (en) 2001-09-26 2006-01-05 Sean Brynjelsen Preparation of submicron solid particle suspensions by sonication of multiphase systems
JP2005508939A (ja) * 2001-10-12 2005-04-07 エラン ファーマ インターナショナル,リミティド 即時放出および徐放特性を組み合わせて有する組成物
US7112340B2 (en) 2001-10-19 2006-09-26 Baxter International Inc. Compositions of and method for preparing stable particles in a frozen aqueous matrix
EP1490025B1 (en) * 2002-03-20 2008-02-13 Elan Pharma International Limited Nanoparticulate compositions of map kinase inhibitors
FR2857592B1 (fr) * 2003-07-18 2006-02-24 Sod Conseils Rech Applic Nouveau procede de preparation de microparticules
US7785612B2 (en) * 2005-04-20 2010-08-31 Taiho Pharmaceutical Co., Ltd. Polyamino acid for use as adjuvant
JP4621218B2 (ja) * 2007-02-09 2011-01-26 有限会社バイオ研 Th1誘導剤及びその製造方法
WO2011026111A1 (en) * 2009-08-31 2011-03-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Oral delivery of a vaccine to the large intestine to induce mucosal immunity

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5417986A (en) 1984-03-16 1995-05-23 The United States Of America As Represented By The Secretary Of The Army Vaccines against diseases caused by enteropathogenic organisms using antigens encapsulated within biodegradable-biocompatible microspheres
IL84167A (en) 1986-10-24 1991-04-15 Southern Res Inst Oral delivery of bioactive agents to and through the peyer's patch by use of microencapsulation
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
JP2743177B2 (ja) * 1987-04-24 1998-04-22 財団法人阪大微生物病研究会 百日咳菌の培養方法、及び百日咳トキソイドとその混合ワクチン
ES2080941T3 (es) * 1990-02-12 1996-02-16 Smithkline Beecham Biolog Nueva vacuna y procedimiento para la misma.
GB9209118D0 (en) * 1992-04-28 1992-06-10 Sb 120 Amsterdam Bv Vaccine compositions
DE69332031T2 (de) 1993-01-08 2002-12-19 Csl Ltd., Parkville Impfstoffpräparate
WO1995011008A2 (en) 1993-10-22 1995-04-27 Genentech, Inc. Methods and compositions for microencapsulation of adjuvants
CA2156718A1 (en) 1993-12-23 1995-06-29 Bruno Gander Immunological response potentiation process
JP3747077B2 (ja) * 1994-04-28 2006-02-22 武田薬品工業株式会社 百日咳菌由来感染防御成分の分離取得方法
ATE252894T1 (de) * 1995-01-05 2003-11-15 Univ Michigan Oberflächen-modifizierte nanopartikel und verfahren für ihre herstellung und verwendung
GB9713156D0 (en) * 1997-06-20 1997-08-27 Microbiological Res Authority Vaccines

Also Published As

Publication number Publication date
JP2002523470A (ja) 2002-07-30
JP4601823B2 (ja) 2010-12-22
CA2341352A1 (en) 2000-03-09
ATE452651T1 (de) 2010-01-15
EP1107782A1 (en) 2001-06-20
CA2341352C (en) 2013-01-08
EP1107782B1 (en) 2009-12-23
EP2168593A1 (en) 2010-03-31
WO2000012124A1 (en) 2000-03-09
DE69941848D1 (de) 2010-02-04

Similar Documents

Publication Publication Date Title
ATE452651T1 (de) Orale impfstoff-zusammensetzung
CA2171844A1 (en) Sustained release formulations for 24 hour release of metoprolol
CA2266403A1 (en) Stable photoprotective compositions
PL308785A1 (en) Agent consisting of a dendrimer and a dendrimer-occluded active substance, method of obtaining such agent and method of releasing active substance therefrom
GB9725084D0 (en) Vaccine compositions
CA2032201A1 (en) Sunscreen compositions
AU1340699A (en) Hyperbranched polymers or dendrimers having a particular group, preparation method and compositions containing same
CA2358707A1 (en) Oral composition for inhibiting oral malodor
CA2161103A1 (en) Controlled Release Oxybutynin Formulations
WO1997002810A3 (en) Polymeric lamellar substrate particles for drug delivery
HK154996A (en) Antiplaque antibacterial oral composition comprising poly(vinyl phosphonic acid)
CA2340221A1 (en) Injectable formulations of nanoparticulate naproxen
PL367896A1 (en) Pharmaceutical compositions comprising colloidal silicon dioxide
AU2472888A (en) Method of solidification and encapsulation using core-shell polymer particles
AU5441299A (en) Method for inducing a cell-mediated immune response and parenteral vaccine formulations therefor
CA2177668A1 (en) Mammalian vaccine compositions comprising squalene or squalane, glycerol and a surfactant as an adjuvant
CA2271623A1 (en) Methods, compositions, and dental delivery systems for the protection of the surfaces of teeth
AU5973390A (en) Encapsulation method, microelectronic devices made therefrom, and heat curable compositions
CA2347195A1 (en) Oral pharmaceutical compositions containing buprenorphin
JP2002523471A5 (cg-RX-API-DMAC7.html)
CA2373867A1 (en) Compositions comprising organosiloxane resins for delivering oral care substances
CA2373868A1 (en) Compositions comprising organosiloxane resins for delivering oral care substances
CA2281054A1 (en) Combination of zinc ions and vitamin c and method of making
NZ295238A (en) Immunogenic compositions characterised by the carrier being a hydrophobic solvent in the absence of a hydrophilic phase
CA2296016A1 (en) Polyoxyalkylene glycol gelatin capsule fill formulations comprising crosslinked carboxylic copolymers

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase